Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

DNTH

Dianthus Therapeutics Inc

Mar 30 • 10:53AM ET

79.77

-1.36 -1.68 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BIIB GILD AMGN MRNA BMY LLY PFE ABBV

| Held by: IWM VTI XBI IWN VXF SCHA IWC VTWO DFAS AVSC

Index	RUT	P/E	-	EPS (ttm)	-4.11	Insider Own	16.67%	Shs Outstand	44.47M	Perf Week	0.57%
Market Cap	4.22B	Forward P/E	-	EPS next Y	-4.81	Insider Trans	-4.80%	Shs Float	44.12M	Perf Month	44.54%
Enterprise Value	3.82B	PEG	-	EPS next Q	-1.06	Inst Own	102.31%	Short Float	20.84%	Perf Quarter	90.70%
Income	-162.34M	P/S	2070.19	EPS this Y	-2.37%	Inst Trans	7.33%	Short Ratio	8.94	Perf Half Y	117.30%
Sales	2.04M	P/B	6.99	EPS next Y	-11.77%	ROA	-35.85%	Short Interest	9.19M	Perf YTD	93.57%
Book/sh	11.42	P/C	10.45	EPS next 5Y	-9.19%	ROE	-38.38%	52W High	88.02 -9.37%	Perf Year	299.05%
Cash/sh	7.64	P/FCF	-	EPS past 3/5Y	49.46% 31.21%	ROIC	-32.83%	52W Low	13.36 496.86%	Perf 3Y	547.06%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-31.80% -	Gross Margin	78.98%	Volatility	5.57% 7.08%	Perf 5Y	-56.38%
Dividend TTM	-	EV/Sales	1872.69	EPS Y/Y TTM	-58.36%	Oper. Margin	-8739.34%	ATR (14)	4.69	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.32	Sales Y/Y TTM	-67.35%	Profit Margin	-7973.33%	RSI (14)	64.75	Recom	1.06
Dividend Gr. 3/5Y	- -	Current Ratio	13.32	EPS Q/Q	-76.48%	SMA20	4.37%	Beta	1.13	Target Price	128.69
Payout	-	Debt/Eq	0.00	Sales Q/Q	-78.58%	SMA50	30.88%	Rel Volume	0.59	Prev Close	81.13
Employees	92	LT Debt/Eq	0.00	Earnings	Mar 09 BMO	SMA200	105.03%	Avg Volume	1.03M	Price	79.77
IPO	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-42.18% -48.57%	Trades		Volume	153,095	Change	-1.68%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-10-26	Upgrade	Raymond James	Outperform → Strong Buy	$123
Oct-14-25	Initiated	Truist	Buy	$56
Jul-02-25	Initiated	William Blair	Outperform
Dec-20-24	Initiated	TD Cowen	Buy
Oct-03-24	Initiated	Oppenheimer	Outperform	$48
Jul-26-24	Initiated	Robert W. Baird	Outperform	$58
Jun-27-24	Initiated	Cantor Fitzgerald	Overweight
May-16-24	Initiated	H.C. Wainwright	Buy	$40
Feb-15-24	Initiated	Stifel	Buy	$44
Dec-26-23	Initiated	Jefferies	Buy	$22
Nov-22-23	Initiated	Wedbush	Outperform	$23
Oct-30-23	Initiated	Guggenheim	Buy	$45
Sep-28-23	Initiated	Raymond James	Outperform	$24
Aug-25-22	Downgrade	Goldman	Buy → Neutral	$2
Jan-06-22	Upgrade	Goldman	Neutral → Buy	$7 → $8
Aug-20-21	Resumed	Goldman	Neutral	$7
Aug-03-21	Downgrade	JP Morgan	Overweight → Neutral	$16 → $7
Jul-22-21	Reiterated	B. Riley Securities	Buy	$21 → $19
Jun-29-21	Initiated	Cantor Fitzgerald	Overweight	$20
Jun-15-21	Initiated	BTIG Research	Buy	$20

Show Previous Ratings

Mar-12-26 04:01PM	Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -6.43%
Mar-11-26 06:05AM	Dianthus 7.3M share Secondary priced at $81.00 (TipRanks)
Mar-10-26 10:54PM	Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering (GlobeNewswire) +9.71%
08:02AM	Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH) (Insider Monkey) +9.71%
Mar-09-26 04:25PM	Dianthus Therapeutics Has Appreciated 12-Fold Over Two Years. What's Going On? (Investor's Business Daily) +21.52%
04:01PM	Loading…
04:01PM	Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering (GlobeNewswire) +21.52% +9.71%
09:22AM	Dianthus Therapeutics Stock Rallies-Rare Disease Study Success Fuels Optimism (Benzinga) +21.52%
08:25AM	Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +21.52%
07:09AM	Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results (GlobeNewswire) +21.52%
07:00AM	Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (GlobeNewswire) +21.52%
Mar-08-26 05:00PM	Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (GlobeNewswire)
Mar-05-26 08:44AM	Dianthus Therapeutics, Inc. (DNTH) Stock Jumps 12.0%: Will It Continue to Soar? (Zacks)
Mar-04-26 09:25AM	Ocugen (OCGN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Mar-03-26 04:01PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-24-26 07:00AM	Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
10:27AM	Loading…
Feb-13-26 10:27AM	Dianthus Therapeutics Conference: DNTH Eyes Q2 2026 CIDP Phase 3 Interim Readout, Expands Pipeline Plans (MarketBeat)
Feb-05-26 07:00AM	Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-23-26 05:42AM	Dianthus Therapeutics, Inc. (DNTH) Moves 9.9% Higher: Will This Strength Last? (Zacks)
Jan-05-26 07:00AM	Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-23-25 06:00AM	Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) (GlobeNewswire)
Dec-05-25 06:35PM	Ashland, Bitdeer, and More Stocks See Action From Activist Investors (Barrons.com)
Nov-24-25 07:00AM	Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference (GlobeNewswire)
Nov-05-25 05:35PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results (GlobeNewswire)
Nov-04-25 05:10PM	Day One Biopharmaceuticals, Inc. (DAWN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:00AM	Dianthus Therapeutics to Participate in Four Investor Conferences During November (GlobeNewswire)
Oct-30-25 10:00AM	Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-29-25 03:30PM	Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting (GlobeNewswire)
Oct-16-25 07:00AM	Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases (GlobeNewswire)
Oct-02-25 08:00AM	Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting (GlobeNewswire)
11:50AM	Loading…
Sep-30-25 11:50AM	Clear Street Initiates Buy on Dianthus Therapeutics, Inc. (DNTH) With $100 Price Target (Insider Monkey)
Sep-19-25 03:26PM	Dianthus, Opendoor, and More Stocks See Action From Activist Investors (Barrons.com)
Sep-11-25 04:07PM	Dianthus Therapeutics, Inc. Announces Closing of its Upsized $288 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Sep-09-25 10:35PM	Dianthus Therapeutics, Inc. Announces Pricing of Upsized $251 Million Underwritten Public Offering (GlobeNewswire)
10:57AM	Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential (Insider Monkey)
07:15AM	Dianthus to take gMG mAb to Phase III after mid-stage win (Clinical Trials Arena)
Sep-08-25 04:00PM	Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering (GlobeNewswire)
02:45PM	Dianthus Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
01:21PM	Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again (Investor's Business Daily)
07:00AM	Dianthus Therapeutics Announces Positive Data for Claseprubart (DNTH103) from the Phase 2 MaGic Trial in Generalized Myasthenia Gravis, Supporting Its Potential Best-In-Class Profile (GlobeNewswire)
Sep-07-25 06:25PM	Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis (GlobeNewswire)
Aug-13-25 04:04PM	The Oncology Institute Announces Changes to Board of Directors (GlobeNewswire)
Aug-07-25 05:20PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results (GlobeNewswire)
10:00AM	Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline (Zacks)
Aug-06-25 06:45PM	Seer, Inc. (SEER) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jun-21-25 03:50PM	Stifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% Upside (Insider Monkey)
May-29-25 07:00AM	Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-25 04:10PM	Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors (GlobeNewswire)
May-12-25 05:10PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results (GlobeNewswire)
May-07-25 05:35PM	Emergent Biosolutions (EBS) Q1 Earnings Top Estimates (Zacks)
May-05-25 07:00AM	Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September (GlobeNewswire)
Apr-29-25 07:00AM	Dianthus Therapeutics to Participate in Two Upcoming Investor Events (GlobeNewswire)
Apr-23-25 02:53PM	Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead (Seeking Alpha)
Apr-03-25 10:03AM	Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock? (Zacks)
Mar-24-25 09:57AM	Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? (Zacks)
Mar-11-25 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results (GlobeNewswire)
Mar-05-25 07:00AM	Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors (GlobeNewswire)
Feb-26-25 07:00AM	Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Jan-30-25 07:00AM	Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences (GlobeNewswire)
Jan-08-25 07:00AM	Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-07-24 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results (GlobeNewswire)
Nov-04-24 07:00AM	Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-15-24 07:00AM	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting (GlobeNewswire)
Sep-04-24 07:00AM	Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September (GlobeNewswire)
Aug-08-24 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results (GlobeNewswire)
Jul-08-24 11:06AM	Dianthus (DNTH) Gains 18% in the Past Month: Here's Why (Zacks)
Jun-28-24 11:30AM	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) (GlobeNewswire)
Jun-12-24 07:00AM	Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN) (GlobeNewswire)
May-30-24 04:30PM	Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-09-24 10:56PM	DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results (GlobeNewswire)
May-08-24 04:30PM	Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference (GlobeNewswire)
May-03-24 04:30PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-11-24 07:30AM	Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire)
Apr-05-24 04:30PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-21-24 10:54PM	DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results (GlobeNewswire)
Mar-07-24 04:30PM	Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-26-24 07:00AM	Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG) (GlobeNewswire)
Feb-23-24 08:00AM	Dianthus Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-31-24 04:05PM	Dianthus Therapeutics to Participate at the Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-22-24 07:30AM	Dianthus Therapeutics Announces $230 Million Private Placement (GlobeNewswire)
Jan-02-24 08:30AM	Dianthus Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-14-23 07:04AM	DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023 (InvestorPlace)
Nov-29-23 04:05PM	Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Nov-09-23 04:05PM	Dianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial Results (GlobeNewswire)
Sep-14-23 05:04PM	Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc (GuruFocus.com)
Aug-14-23 01:35PM	CEO of shuttered biotech Magenta Therapeutics makes leap to Flagship startup (American City Business Journals)
May-03-23 04:19PM	Magenta Sets Up Dianthus Merger After Stopping Blood Cancer Trial Due To Patient Death (Benzinga)
07:00AM	Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement (GlobeNewswire)
Mar-31-23 04:10PM	Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan (GlobeNewswire)
06:09AM	The Zacks Analyst Blog Highlights Blue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta Therapeutics (Zacks)
Mar-27-23 10:20AM	Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Feb-09-23 01:24PM	On eve of shutdown, Cambridge biotech loses 84% of staff, including 5 execs (American City Business Journals)
10:13AM	Magenta's CEO Leaves After Patient Death Halts Trials, Shuttering Concerns Looms (Benzinga)
Feb-03-23 01:35PM	Magenta Therapeutics to shut down after patient death (American City Business Journals)
Feb-02-23 04:05PM	Magenta Therapeutics to Explore Strategic Alternatives (GlobeNewswire)
05:58AM	The Petri Dish: Departed White House adviser returns to the Broad (American City Business Journals)

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Soteropoulos Paula	Director	Mar 24 '26	Option Exercise	8.44	27,594	232,893	27,594	Mar 26 06:00 PM
Soteropoulos Paula	Director	Mar 24 '26	Sale	78.05	27,594	2,153,712	0	Mar 26 06:00 PM
PAULA C SOTEROPOULOS	Director	Mar 24 '26	Proposed Sale	79.32	27,594	2,188,756		Mar 24 04:29 PM
Garcia Marino	CEO AND PRESIDENT	Mar 16 '26	Option Exercise	7.66	65,292	499,975	65,292	Mar 17 05:22 PM
Garcia Marino	CEO AND PRESIDENT	Mar 12 '26	Option Exercise	6.70	122,918	823,551	122,918	Mar 13 08:30 PM
Garcia Marino	CEO AND PRESIDENT	Mar 12 '26	Sale	81.49	122,918	10,016,381	0	Mar 13 08:30 PM
CARR EDWARD	CHIEF ACCOUNTING OFFICER	Mar 12 '26	Option Exercise	20.45	43,682	893,259	43,682	Mar 13 08:30 PM
CARR EDWARD	CHIEF ACCOUNTING OFFICER	Mar 12 '26	Sale	81.49	43,682	3,559,495	0	Mar 13 08:30 PM
Randhawa Simrat	EVP, Head of R&D	Mar 12 '26	Option Exercise	18.15	33,830	614,166	33,830	Mar 13 08:30 PM
Randhawa Simrat	EVP, Head of R&D	Mar 12 '26	Sale	81.48	33,830	2,756,468	0	Mar 13 08:30 PM
MARINO GARCIA	Director	Mar 12 '26	Proposed Sale	85.84	122,918	10,551,281		Mar 12 04:59 PM
SIMRAT RANDHAWA	Officer	Mar 12 '26	Proposed Sale	85.84	33,830	2,903,967		Mar 12 04:30 PM
EDWARD CARR	Officer	Mar 12 '26	Proposed Sale	85.84	43,682	3,749,663		Mar 12 04:23 PM
Savitz Ryan	CFO & CBO	Dec 04 '25	Option Exercise	8.44	20,000	168,800	20,000	Dec 05 08:00 PM
Savitz Ryan	CFO & CBO	Dec 04 '25	Sale	45.18	20,000	903,600	0	Dec 05 08:00 PM
RYAN SAVITZ	Officer	Dec 04 '25	Proposed Sale	43.97	20,000	879,400		Dec 04 04:42 PM
Randhawa Simrat	EVP, Head of R&D	Nov 14 '25	Option Exercise	20.42	109,031	2,226,263	113,031	Nov 14 09:00 PM
Randhawa Simrat	EVP, Head of R&D	Nov 13 '25	Option Exercise	8.82	87,507	771,873	91,507	Nov 14 09:00 PM
Randhawa Simrat	EVP, Head of R&D	Nov 14 '25	Sale	38.14	109,031	4,158,442	4,000	Nov 14 09:00 PM
Randhawa Simrat	EVP, Head of R&D	Nov 13 '25	Sale	36.81	87,507	3,221,445	4,000	Nov 14 09:00 PM
SIMRAT RANDHAWA	Officer	Nov 13 '25	Proposed Sale	38.72	196,538	7,609,951		Nov 13 04:23 PM
Savitz Ryan	CFO & CBO	Sep 09 '25	Option Exercise	8.44	20,000	168,800	20,000	Sep 11 05:20 PM
Savitz Ryan	CFO & CBO	Sep 09 '25	Sale	35.00	20,000	700,000	0	Sep 11 05:20 PM
RYAN SAVITZ	Officer	Sep 09 '25	Proposed Sale	31.80	20,000	636,000		Sep 09 04:27 PM

Open in Screener

QURE

uniQure N.V

Mar 30 • 10:53AM ET

14.93

+0.16 1.08 %

Healthcare • Biotechnology • Netherlands • NASD

Peers: SRPT BLUE CRSP BMRN NTLA SGMO RCKT EDIT ADVM BOLD

| Held by: XBI VXF IBB SCHA KOMP JGRO LABU ITOT SCHB GNOM

Index	-	P/E	-	EPS (ttm)	-3.48	Insider Own	9.97%	Shs Outstand	62.34M	Perf Week	-6.22%
Market Cap	919.75M	Forward P/E	-	EPS next Y	-2.95	Insider Trans	-3.29%	Shs Float	55.46M	Perf Month	-4.48%
Enterprise Value	833.80M	PEG	-	EPS next Q	-0.87	Inst Own	98.14%	Short Float	22.93%	Perf Quarter	-39.82%
Income	-198.97M	P/S	57.13	EPS this Y	-0.97%	Inst Trans	10.22%	Short Ratio	3.86	Perf Half Y	-72.51%
Sales	16.10M	P/B	4.68	EPS next Y	15.60%	ROA	-28.81%	Short Interest	12.72M	Perf YTD	-37.61%
Book/sh	3.19	P/C	1.48	EPS next 5Y	9.03%	ROE	-207.10%	52W High	71.50 -79.12%	Perf Year	19.73%
Cash/sh	10.11	P/FCF	-	EPS past 3/5Y	-8.45% -4.24%	ROIC	-27.20%	52W Low	7.76 92.40%	Perf 3Y	-24.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-46.73% -15.57%	Gross Margin	-2.16%	Volatility	8.61% 12.99%	Perf 5Y	-55.15%
Dividend TTM	-	EV/Sales	51.79	EPS Y/Y TTM	29.32%	Oper. Margin	-1202.09%	ATR (14)	1.85	Perf 10Y	26.96%
Dividend Ex-Date	-	Quick Ratio	10.43	Sales Y/Y TTM	-40.64%	Profit Margin	-1236.00%	RSI (14)	43.24	Recom	1.57
Dividend Gr. 3/5Y	- -	Current Ratio	10.43	EPS Q/Q	60.34%	SMA20	-0.36%	Beta	0.80	Target Price	37.08
Payout	-	Debt/Eq	2.70	Sales Q/Q	6.65%	SMA50	-24.61%	Rel Volume	0.21	Prev Close	14.77
Employees	221	LT Debt/Eq	2.68	Earnings	Mar 02 BMO	SMA200	-40.58%	Avg Volume	3.29M	Price	14.93
IPO	Feb 05, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	37.63% 4.49%	Trades		Volume	177,594	Change	1.08%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-26	Upgrade	Mizuho	Neutral → Outperform	$35
Mar-09-26	Upgrade	Wells Fargo	Equal Weight → Overweight	$60
Mar-09-26	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$35
Mar-03-26	Downgrade	Wells Fargo	Overweight → Equal Weight	$15
Mar-03-26	Downgrade	Mizuho	Outperform → Neutral	$12
Mar-02-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$11
Mar-02-26	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$9
Feb-24-26	Initiated	Wolfe Research	Peer Perform
Jan-28-26	Initiated	Barclays	Equal Weight	$31
Nov-04-25	Downgrade	William Blair	Outperform → Mkt Perform
Aug-14-25	Upgrade	Mizuho	Neutral → Outperform	$30
Apr-01-25	Resumed	Chardan Capital Markets	Buy	$38
Dec-10-24	Upgrade	Raymond James	Outperform → Strong Buy
Oct-10-24	Resumed	Raymond James	Outperform	$20
Feb-29-24	Downgrade	Goldman	Buy → Neutral	$8
Dec-19-23	Downgrade	Mizuho	Buy → Neutral	$52 → $10
Mar-17-22	Upgrade	UBS	Neutral → Buy	$40
Jun-15-21	Initiated	BTIG Research	Buy	$46
May-21-21	Initiated	UBS	Neutral	$40
Apr-26-21	Resumed	Credit Suisse	Outperform	$78

Show Previous Ratings

Mar-20-26 03:23AM	uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE (PR Newswire) +5.44%
Mar-10-26 08:17AM	uniQure Shares Surge 26% On US FDA Shakeup Even As Momentum Tumbles: Will New Leadership Greenlight Huntington's Therapy? (Benzinga)
Mar-09-26 04:37PM	This biotech's stock soared after a 'polarizing' FDA official is stepping down (MarketWatch) +26.07%
01:32PM	What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (Benzinga) +26.07%
01:15PM	Biotech Stocks Rally on Departure of Polarizing FDA Official (The Wall Street Journal) +26.07%
11:17AM	Loading…
11:17AM	uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts (24/7 Wall St.) +26.07%
08:23AM	uniQure stock surges 36% on FDA officials departure (Investing.com) +26.07%
07:01AM	Why Is uniQure Stock Skyrocketing Monday? (Benzinga) +26.07%
05:28AM	Stock Market Today: Dow Jones, S&P 500 Futures Plunge As Oil Prices Jump, Trump Dismisses 'Short Term' Spike-Hims & Hers, Ovintiv, Uniqure In Focus (Benzinga) +26.07%
Mar-06-26 07:13PM	FDA Vaccine Chief Vinay Prasad Set to Leave Post Next Month (Bloomberg) +33.99%
09:57AM	QURE Stock Crashes 32% in a Week: Here's What You Should Know (Zacks) +33.99%
Mar-05-26 06:01PM	Federal Health Officials Attack Rare-Disease Drug, Say Company Lied (The Wall Street Journal) +17.81%
12:11PM	FDA Defends Call For Placebo Study In uniQure Huntington's Gene Therapy Trial (Benzinga) +17.81%
Mar-04-26 09:58AM	What's Going On With uniQure Stock Wednesday? (Benzinga)
09:35AM	uniQure (QURE) Loses 67.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
11:38AM	Loading…
Mar-03-26 11:38AM	uniQure downgraded after FDA backs sham-controlled trial for Huntingtons therapy (Investing.com) -14.00%
09:33AM	MongoDB downgraded, Block upgraded: Wall Street's top analyst calls (The Fly) -14.00%
08:00AM	Here Are Tuesdays Top Wall Street Analyst Research Calls: Block, CrowdStrike, Fortinet, MongoDB, Mosaic, Palo Alto Networks, Unity Software, and More (24/7 Wall St.) -14.00%
Mar-02-26 04:37PM	Stocks Recover as Iran War Pushes Energy and Defense Stocks Higher (Barchart) -32.82%
04:28PM	Uniqure Plummets By A Third After Realizing 'The Worst Case Scenario' For Its Gene Therapy (Investor's Business Daily) -32.82% -14.00%
02:01PM	uniQure NV (QURE) Q4 2025 Earnings Call Highlights: Breakthroughs and Challenges in Gene Therapy (GuruFocus.com) -32.82%
12:57PM	FDA tells uniQure to conduct another study of Huntingtons gene therapy (Clinical Trials Arena) -32.82%
12:33PM	uniQure N.V. Q4 2025 Earnings Call Summary (Moby) -32.82%
11:37AM	UniQure Stock Drops 36% After Earnings. Bad News From the FDA Gets Even Worse. (Barrons.com) -32.82%
11:19AM	Markets Rebound After Initial Selloff Triggered by Middle East Tensions (Barchart) -32.82%
10:37AM	uniQure Q4 Earnings Call Highlights (MarketBeat) -32.82%
08:58AM	Uniqure Plummets More Than 40% On Another Twist In Its Gene Therapy Saga (Investor's Business Daily) -32.82%
08:51AM	uniQure Stock Plunges 40% After FDA Shocker (Benzinga) -32.82%
08:20AM	uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -32.82%
07:20AM	UniQure: Q4 Earnings Snapshot (Associated Press Finance) -32.82%
07:05AM	Loading…
07:05AM	uniQure Announces 2025 Financial Results and Provides Recent Company Updates (GlobeNewswire) -32.82%
07:00AM	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease (GlobeNewswire) -32.82%
Feb-28-26 02:21AM	Wolfe Research Initiates Coverage of UniQure (QURE) With a Peer Perform Rating (Insider Monkey)
Feb-27-26 12:49AM	QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? (New feeds test provider finance)
Feb-26-26 04:06PM	Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug (Investor's Business Daily)
09:55AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-23-26 07:05AM	uniQure to Announce 2025 Financial Results (GlobeNewswire)
Feb-18-26 09:00AM	uniQure N.V. Sued for Securities Law Violations - Contact Levi & Korsinsky Before April 13, 2026 to Discuss Your Rights - QURE (PR Newswire)
Feb-14-26 01:28AM	UniQure (QURE) Reports Positive Phase I/IIa AMT-191 Data for Fabry Disease, Shows Sustained Enzyme Activity (Insider Monkey)
Feb-13-26 01:11AM	uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - QURE (PR Newswire)
Feb-12-26 08:00AM	uniQure N.V. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights QURE (Business Wire)
Feb-06-26 01:58PM	Early uniQure Fabry Trial Shows Lasting Enzyme Boost, Safety Watch (Benzinga)
07:05AM	uniQure Announces Updated Preliminary AMT-191 Phase I/IIa Data Showing Sustained Increases in a-Gal A Enzyme Activity in Patients with Fabry Disease (GlobeNewswire)
Feb-02-26 09:35AM	uniQure (QURE) Navigates Gene Therapy Development as Investors Weigh Long-Term Potential (Insider Monkey)
Jan-20-26 09:01AM	Here's Why uniQure (QURE) Fell in Q3 (Insider Monkey)
Jan-12-26 10:11AM	Is UniQure (QURE) One of the Promising Stocks to Buy Under $50? (Insider Monkey)
Jan-09-26 01:14PM	uniQure Stock Jumps After Scheduling FDA Type A Meeting For AMT-130 Approval Pathway (Benzinga)
07:05AM	uniQure Announces Type A Meeting Scheduled with FDA (GlobeNewswire)
Dec-21-25 09:56AM	What Do Analysts Think About UniQure (QURE)? (Insider Monkey)
Dec-15-25 11:11PM	UniQure (QURE) Stock Drop Looms as FDA Concern Over Huntington's Data Spurs Mizuho Downgrade and Delayed Launch (Insider Monkey)
Dec-04-25 12:18PM	uniQure N.V. (QURE): A Bear Case Theory (Insider Monkey)
10:02AM	UniQure Plummets, Again, As FDA Indicates It Will Reject Huntington's Gene Therapy (Investor's Business Daily)
07:05AM	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease (GlobeNewswire)
Nov-25-25 08:39AM	William Blair Maintains Market Perform Rating on uniQure (QURE) Despite AMT-130 Approval Uncertainty (Insider Monkey)
Nov-19-25 08:16AM	Summers Value Partners Established a Position in UniQure N.V. (QURE) in Q3 (Insider Monkey)
Nov-17-25 12:15PM	Wall Street Has a Positive Outlook on uniQure N.V. (QURE) Despite Challenges From The FDA (Insider Monkey)
Nov-12-25 07:00AM	uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences (Insider Monkey)
Nov-10-25 04:01PM	uniQure NV (QURE) Q3 2025 Earnings Call Highlights: Promising Data Amid Regulatory Challenges (GuruFocus.com)
08:15AM	uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:14AM	UniQure: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-25 07:05AM	uniQure to Announce Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-05-25 04:28PM	Biohaven Craters After FDA Unexpectedly Rejects Its High-Profile Drug (Investor's Business Daily)
Nov-04-25 01:36PM	FDA halts uniQures plans for Huntingtons disease gene therapy (Pharmaceutical Technology)
Nov-03-25 04:29PM	These Stocks Moved the Most Today: Kenvue, Kimberly-Clark, Amazon, uniQure, Palantir, Idexx, Cipher Mining, and More (Barrons.com)
04:27PM	UniQure Plummets 49% On A 'Confusing' And 'Unexpected' Twist For Its Gene Therapy (Investor's Business Daily)
11:15AM	uniQure (QURE) Price Targets Raised by Analysts After Positive Trial Results (Insider Monkey)
08:33AM	UniQure Stock Plummets 67% on Potential FDA Decision. Here's Why. (Barrons.com)
07:05AM	uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease (GlobeNewswire)
Oct-30-25 10:00AM	Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-28-25 10:00AM	uniQure (QURE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-23-25 08:16AM	Breakout Momentum Plays You Need to Know About (MarketBeat)
Oct-22-25 04:58PM	uniQure N.V. (QURE): A Bull Case Theory (Insider Monkey)
Oct-19-25 03:09AM	H.C. Wainwright Raises the PT on uniQure N.V. (QURE), Keeps a Buy Rating (Insider Monkey)
Oct-13-25 05:30AM	Why Biotech's Rally Can Last This Time (The Wall Street Journal)
Oct-08-25 05:34AM	Jim Cramer on uniQure: "This One Has Too Many Questions for Me Up Here" (Insider Monkey)
Oct-03-25 04:14PM	QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop (MarketBeat)
Sep-30-25 12:46PM	uniQure N.V. (QURE) Reports Positive Phase I/II Results, Prepares FDA BLA Submission (Insider Monkey)
Sep-29-25 06:28PM	uniQurex (QURE) Nearly Quadruples on Stellar Results for Huntington Disease Treatment (Insider Monkey)
04:05PM	uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
Sep-25-25 11:38PM	uniQure Announces Pricing of Upsized $300 Million Public Offering (GlobeNewswire)
11:07AM	QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study (Zacks)
10:23AM	Uniqure (QURE) Soars 275% on Stellar Clinical Trial for Huntington's Disease (Insider Monkey)
09:36AM	Stocks to Watch Thursday: Intel, Oracle, CarMax, Accenture (The Wall Street Journal)
09:15AM	Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus (PR Newswire)
06:24AM	Strength Seen in uniQure (QURE): Can Its 247.7% Jump Turn into More Strength? (Zacks)
Sep-24-25 04:37PM	Here's why biotech UniQure's stock just tripled, and brought ClearPoint shares up with it (MarketWatch)
04:21PM	A Cure For Huntington's Disease? UniQure Launches Nearly 250%. (Investor's Business Daily)
04:06PM	uniQure Announces $200 Million Proposed Public Offering (GlobeNewswire)
10:23AM	uniQure Stock Doubles On Promising Data From Huntington's Disease Trial (Benzinga)
07:10AM	uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding (GlobeNewswire)
07:05AM	uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington's Disease (GlobeNewswire)
Sep-18-25 09:10AM	Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics (PR Newswire)
Sep-05-25 07:05AM	uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in a-Gal A Enzyme Activity in Patients with Fabry Disease (GlobeNewswire)
Jul-31-25 09:55AM	Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet (Zacks)
Jul-29-25 08:15AM	uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:13AM	UniQure: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress (GlobeNewswire)
Jul-22-25 07:05AM	uniQure to Announce Second Quarter 2025 Financial Results (GlobeNewswire)
Jun-23-25 01:38AM	Lake Street: AMT-130 Could Be Game-Changer For ClearPoint (Insider Monkey)

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kapusta Matthew C	CEO, Managing Director	Mar 04 '26	Sale	9.06	14,581	132,104	660,658	Mar 06 05:07 PM
Abi-Saab Walid	Chief Medical Officer	Mar 04 '26	Sale	9.06	808	7,320	189,669	Mar 06 04:59 PM
Potts Jeannette	Chief Legal Officer	Mar 04 '26	Sale	9.06	3,412	30,913	138,483	Mar 06 04:35 PM
KLEMT CHRISTIAN	Chief Financial Officer	Mar 04 '26	Sale	9.06	12,000	108,720	226,581	Mar 06 04:30 PM
Potts Jeannette	Officer	Mar 04 '26	Proposed Sale	9.06	3,412	30,927		Mar 04 04:56 PM
KLEMT CHRISTIAN	Officer	Mar 04 '26	Proposed Sale	9.06	12,000	108,770		Mar 04 04:50 PM
Kapusta Matthew C	Director	Mar 04 '26	Proposed Sale	9.06	14,581	132,165		Mar 04 04:46 PM
Kapusta Matthew C	CEO, Managing Director	Mar 02 '26	Sale	9.95	34,437	342,648	604,639	Mar 04 04:42 PM
KLEMT CHRISTIAN	Chief Financial Officer	Mar 02 '26	Sale	9.95	12,532	124,693	198,981	Mar 04 04:36 PM
Potts Jeannette	Chief Legal Officer	Mar 02 '26	Sale	9.95	8,578	85,351	106,495	Mar 04 04:31 PM
Abi-Saab Walid	Chief Medical Officer	Mar 02 '26	Sale	9.95	1,660	16,517	148,777	Mar 04 04:25 PM
Kapusta Matthew C	Director	Mar 02 '26	Proposed Sale	9.95	34,437	342,586		Mar 02 05:39 PM
KLEMT CHRISTIAN	Officer	Mar 02 '26	Proposed Sale	9.95	12,832	127,655		Mar 02 05:29 PM
Potts Jeannette	Officer	Mar 02 '26	Proposed Sale	9.95	8,578	85,336		Mar 02 05:23 PM
Kapusta Matthew C	CEO, Managing Director	Feb 25 '26	Sale	23.86	12,378	295,339	639,076	Feb 27 04:49 PM
KLEMT CHRISTIAN	Chief Financial Officer	Feb 25 '26	Sale	23.86	6,217	148,338	211,513	Feb 27 04:42 PM
Kapusta Matthew C	Director	Feb 25 '26	Proposed Sale	23.86	12,378	295,307		Feb 25 04:07 PM
KLEMT CHRISTIAN	Officer	Feb 25 '26	Proposed Sale	23.86	6,217	148,321		Feb 25 04:01 PM
Gut Robert	Director	Jan 12 '26	Option Exercise	14.08	17,810	250,765	57,955	Jan 14 04:26 PM
Gut Robert	Director	Jan 12 '26	Sale	24.62	25,613	630,483	32,342	Jan 14 04:26 PM
Kaye Jack	Director	Jan 09 '26	Option Exercise	19.39	6,390	123,902	26,829	Jan 12 04:21 PM
Kaye Jack	Director	Jan 09 '26	Sale	27.28	6,390	174,319	20,439	Jan 12 04:21 PM
Gut Robert	Director	Jan 12 '26	Proposed Sale	26.42	25,613	676,695		Jan 12 03:59 PM
Kaye Jack	Director	Jan 09 '26	Proposed Sale	27.28	6,390	174,330		Jan 09 03:59 PM
Gut Robert	Director	Nov 06 '25	Option Exercise	4.57	15,840	72,389	71,579	Nov 10 04:54 PM
Gut Robert	Director	Nov 06 '25	Sale	27.26	31,434	856,881	40,145	Nov 10 04:54 PM
Kaye Jack	Director	Nov 04 '25	Option Exercise	9.88	38,810	383,535	38,249	Nov 06 05:01 PM
Kaye Jack	Director	Nov 04 '25	Sale	30.34	38,810	1,177,517	20,439	Nov 06 05:01 PM
Gut Robert	Director	Nov 06 '25	Proposed Sale	26.06	31,434	819,170		Nov 06 04:13 PM
Kaye Jack	Director	Nov 04 '25	Proposed Sale	34.29	38,810	1,330,794		Nov 04 04:00 PM
Kapusta Matthew C	CEO, Managing Director	Sep 24 '25	Option Exercise	6.52	226,316	1,474,909	877,770	Sep 26 07:43 PM
Kapusta Matthew C	CEO, Managing Director	Sep 24 '25	Sale	41.46	226,316	9,382,473	651,454	Sep 26 07:43 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 26 '25	Option Exercise	5.37	15,000	80,550	232,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 24 '25	Option Exercise	13.03	3,000	39,090	220,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 26 '25	Sale	55.00	15,000	825,000	217,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Chief Financial Officer	Sep 24 '25	Sale	40.04	3,000	120,120	217,730	Sep 26 07:37 PM
KLEMT CHRISTIAN	Officer	Sep 26 '25	Proposed Sale	55.00	15,000	825,000		Sep 26 04:04 PM
KLEMT CHRISTIAN	Officer	Sep 24 '25	Proposed Sale	40.00	3,000	120,000		Sep 24 08:01 PM
Kapusta Matthew C	Director	Sep 24 '25	Proposed Sale	41.45	226,316	9,381,750		Sep 24 07:59 PM
Abi-Saab Walid	Chief Medical Officer	Jun 27 '25	Sale	13.92	1,466	20,407	150,437	Jul 01 04:49 PM
Springhorn Jeremy P.	Director	Jun 20 '25	Sale	14.45	2,112	30,518	37,694	Jun 24 06:08 PM
POST LEONARD E	Director	Jun 20 '25	Sale	14.45	2,112	30,518	29,937	Jun 24 06:03 PM
Kaye Jack	Director	Jun 20 '25	Sale	14.45	2,112	30,518	20,439	Jun 24 05:53 PM
Jacques Rachelle Suzanne	Director	Jun 20 '25	Sale	14.45	2,112	30,518	28,346	Jun 24 05:50 PM
Gut Robert	Director	Jun 20 '25	Sale	14.45	3,336	48,205	56,879	Jun 24 05:45 PM
Balachandran Madhavan	Director	Jun 20 '25	Sale	14.45	2,112	30,518	37,697	Jun 24 05:42 PM
Meek David D.	Director	Jun 20 '25	Sale	14.45	2,112	30,518	34,190	Jun 24 05:34 PM
Potts Jeannette	Chief Legal Officer	Jun 16 '25	Sale	15.14	4,670	70,704	115,073	Jun 20 07:43 PM

DNTH

Dianthus Therapeutics Inc

QURE

uniQure N.V

Upgrade your Finviz experience